Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemothera...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Leijen, Suzanne, van Geel, Robin M.J.M., Pavlick, Anna C., Tibes, Raoul, Rosen, Lee, Razak, Albiruni R. Abdul, Lam, Raymond, Demuth, Tim, Rose, Shelonitda, Lee, Mark A., Freshwater, Tomoko, Shumway, Stuart, Liang, Li Wen, Oza, Amit M., Schellens, Jan H.M., Shapiro, Geoffrey I.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2016
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845944/
https://ncbi.nlm.nih.gov/pubmed/27601554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.5991
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items